A Study of an Investigational Study Drug for Benign Prostatic Hyperplasia (0906-140)
Phase 3
Completed
- Conditions
- Benign Prostatic Hyperplasia
- Registration Number
- NCT00127179
- Lead Sponsor
- Organon and Co
- Brief Summary
The purpose of this trial is to determine the efficacy and safety of an investigational drug in patients with benign prostatic hyperplasia.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 600
Inclusion Criteria
- Patients with benign prostatic hyperplasia
Exclusion Criteria
- Patients who are suspected to be suffering from prostatic cancer
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Change from baseline in the International Prostate Symptom Score
- Secondary Outcome Measures
Name Time Method Change from baseline in Prostate volume Change from baseline in maximum urinary flow rate, % Change from baseline in QOL - index